BioStock: Coegin Pharma - generating value and reducing risk in 2021

With the release of their annual report, Coegin Pharma puts into perspective its main goal of developing a better treatment alternative for cancerous as well as pre-cancerous indications like actinic keratosis. With this goal in mind, the company will be focused on building value and reducing risk for its shareholders in 2021.

Read the full article at biostock.se:

https://www.biostock.se/en/coegin-pharma-generating-value-and-reducing-risk-in-2021/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/